Literature DB >> 22141738

Modulation of T cell immune functions by the prostaglandin E(2) - cAMP pathway in chronic inflammatory states.

Kristoffer Watten Brudvik1, Kjetil Taskén.   

Abstract

Cyclic AMP is the intracellular second messenger for a variety of immunoregulatory inflammatory mediators such as prostaglandin E2, adenosine and histamine that signal to effector T cells from monocytes, macrophages and regulatory T cells. Protein kinase A (PKA) type I localizes to lipid rafts in effector T cells during T cell activation and directly modulates proximal signal events including phosphorylation of C-terminal Src kinase (Csk), which initiates a negative signal pathway that fine-tunes the T cell activation process. The PKA-Csk immunoregulatory pathway is scaffolded by the A kinase anchoring protein ezrin, the Csk binding protein phosphoprotein associated with glycosphingolipid-enriched membrane microdomains and the linker protein ezrin/radixin/moesin binding protein of 50 kDa. This pathway is hyperactivated in chronic infections with an inflammatory component such as HIV, other immunodeficiencies and around solid tumours as a consequence of local inflammation leading to inhibition of anti-tumour immunity. LINKED ARTICLES This article is part of a themed section on Novel cAMP Signalling Paradigms. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.166.issue-2.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22141738      PMCID: PMC3417476          DOI: 10.1111/j.1476-5381.2011.01800.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  88 in total

Review 1.  Molecular mechanisms for protein kinase A-mediated modulation of immune function.

Authors:  Knut Martin Torgersen; Torkel Vang; Hilde Abrahamsen; Sheraz Yaqub; Kjetil Taskén
Journal:  Cell Signal       Date:  2002-01       Impact factor: 4.315

Review 2.  Cyclic nucleotide phosphodiesterases.

Authors:  D M Essayan
Journal:  J Allergy Clin Immunol       Date:  2001-11       Impact factor: 10.793

Review 3.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.

Authors:  R A Gupta; R N Dubois
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

4.  Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection.

Authors:  Janis V Giorgi; Robert H Lyles; Jose L Matud; Traci E Yamashita; John W Mellors; Lance E Hultin; Beth D Jamieson; Joseph B Margolick; Charles R Rinaldo; John P Phair; Roger Detels
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-01       Impact factor: 3.731

5.  Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes.

Authors:  Hiroshi Tanaka; Junta Tanaka; Jørgen Kjaergaard; Suyu Shu
Journal:  J Immunother       Date:  2002 May-Jun       Impact factor: 4.456

Review 6.  Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance.

Authors:  S Sakaguchi; N Sakaguchi; J Shimizu; S Yamazaki; T Sakihama; M Itoh; Y Kuniyasu; T Nomura; M Toda; T Takahashi
Journal:  Immunol Rev       Date:  2001-08       Impact factor: 12.988

Review 7.  Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases.

Authors:  M Delgado; C Abad; C Martinez; M G Juarranz; A Arranz; R P Gomariz; J Leceta
Journal:  J Mol Med (Berl)       Date:  2001-10-17       Impact factor: 4.599

8.  Inhibition of antigen-specific T cell proliferation and cytokine production by protein kinase A type I.

Authors:  Einar Martin Aandahl; Walter J Moretto; Patrick A Haslett; Torkel Vang; Tone Bryn; Kjetil Tasken; Douglas F Nixon
Journal:  J Immunol       Date:  2002-07-15       Impact factor: 5.422

Review 9.  Cyclic nucleotide-gated ion channels.

Authors:  U Benjamin Kaupp; Reinhard Seifert
Journal:  Physiol Rev       Date:  2002-07       Impact factor: 37.312

10.  Increased activation of protein kinase A type I contributes to the T cell deficiency in common variable immunodeficiency.

Authors:  P Aukrust; E M Aandahl; B S Skålhegg; I Nordøy; V Hansson; K Taskén; S S Frøland; F Müller
Journal:  J Immunol       Date:  1999-01-15       Impact factor: 5.422

View more
  24 in total

1.  Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis.

Authors:  C González-García; B Bravo; A Ballester; R Gómez-Pérez; C Eguiluz; M Redondo; A Martínez; C Gil; S Ballester
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

2.  PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis.

Authors:  L Mestre; M Redondo; F J Carrillo-Salinas; J A Morales-García; S Alonso-Gil; A Pérez-Castillo; C Gil; A Martínez; C Guaza
Journal:  Br J Pharmacol       Date:  2015-07-14       Impact factor: 8.739

3.  Combined use of pharmacophoric models together with drug metabolism and genotoxicity "in silico" studies in the hit finding process.

Authors:  Ma José Jerez; Miguel Jerez; Coral González-García; Sara Ballester; Ana Castro
Journal:  J Comput Aided Mol Des       Date:  2013-01-08       Impact factor: 3.686

4.  Prostaglandin E2 Inhibition of IL-27 Production in Murine Dendritic Cells: A Novel Mechanism That Involves IRF1.

Authors:  Kirsten M Hooper; Jui-Hung Yen; Weimin Kong; Kate M Rahbari; Ping-Chang Kuo; Ana M Gamero; Doina Ganea
Journal:  J Immunol       Date:  2017-01-06       Impact factor: 5.422

5.  Lipoic Acid Stimulates cAMP Production in Healthy Control and Secondary Progressive MS Subjects.

Authors:  Sarah E Fiedler; Vijayshree Yadav; Amelia R Kerns; Catherine Tsang; Sheila Markwardt; Edward Kim; Rebecca Spain; Dennis Bourdette; Sonemany Salinthone
Journal:  Mol Neurobiol       Date:  2017-11-15       Impact factor: 5.590

6.  Prostaglandin E2/EP2 receptor signalling pathway promotes diabetic retinopathy in a rat model of diabetes.

Authors:  Man Wang; Yangningzhi Wang; Tianhua Xie; Pengfei Zhan; Jian Zou; Xiaowei Nie; Jun Shao; Miao Zhuang; Chengye Tan; Jianxin Tan; Youai Dai; Jie Sun; Jiantao Li; Yuehua Li; Qian Shi; Jing Leng; Xiaolu Wang; Yong Yao
Journal:  Diabetologia       Date:  2018-11-08       Impact factor: 10.122

7.  Persistent immune activation in chronic HIV infection: do any interventions work?

Authors:  Reena Rajasuriar; Gabriela Khoury; Adeeba Kamarulzaman; Martyn A French; Paul U Cameron; Sharon R Lewin
Journal:  AIDS       Date:  2013-05-15       Impact factor: 4.177

8.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

9.  Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization.

Authors:  Kheng Newick; Shaun O'Brien; Jing Sun; Veena Kapoor; Steven Maceyko; Albert Lo; Ellen Puré; Edmund Moon; Steven M Albelda
Journal:  Cancer Immunol Res       Date:  2016-04-04       Impact factor: 11.151

10.  Proinflammatory and immunoregulatory roles of eicosanoids in T cells.

Authors:  Anna Mari Lone; Kjetil Taskén
Journal:  Front Immunol       Date:  2013-06-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.